GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nkarta Inc (NAS:NKTX) » Definitions » Market Cap

Nkarta (Nkarta) Market Cap : $453.81 Mil (As of May. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nkarta Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Nkarta's share price for the quarter that ended in Mar. 2024 was $10.81. Nkarta's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 70.45 Mil. Therefore, Nkarta's market cap for the quarter that ended in Mar. 2024 was $761.60 Mil.

Nkarta's quarterly market cap increased from Sep. 2023 ($68.20 Mil) to Dec. 2023 ($324.60 Mil) and increased from Dec. 2023 ($324.60 Mil) to Mar. 2024 ($761.60 Mil).

Nkarta's annual market cap declined from Dec. 2021 ($506.11 Mil) to Dec. 2022 ($292.78 Mil) but then increased from Dec. 2022 ($292.78 Mil) to Dec. 2023 ($324.60 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Nkarta's Enterprise Value for Today is $103.59 Mil.


Nkarta Market Cap Historical Data

The historical data trend for Nkarta's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nkarta Market Cap Chart

Nkarta Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial - 2,005.64 506.11 292.78 324.60

Nkarta Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 173.70 107.44 68.20 324.60 761.60

Competitive Comparison of Nkarta's Market Cap

For the Biotechnology subindustry, Nkarta's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nkarta's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nkarta's Market Cap distribution charts can be found below:

* The bar in red indicates where Nkarta's Market Cap falls into.



Nkarta Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Nkarta's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$6.6*49.1813
=$324.60

Nkarta's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$10.81*70.4536
=$761.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nkarta  (NAS:NKTX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Nkarta Market Cap Related Terms

Thank you for viewing the detailed overview of Nkarta's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Nkarta (Nkarta) Business Description

Traded in Other Exchanges
N/A
Address
6000 Shoreline Court, Suite 102, South San Francisco, CA, USA, 94080
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
Executives
Paul J Hastings director, officer: See Remarks 61 HARTFORD STREET, SAN FRANCISCO CA 94114
David Shook officer: Chief Medical Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alicia J. Hager officer: Chief Legal Officer C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Ralph Brandenberger officer: Sr. VP, Technical Operations 6000 SHORELINE COURT, SUITE 102, SAN FRANCISCO CA 94080
James Trager officer: Chief Scientific Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alyssa Levin officer: See Remarks 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Nadir Mahmood officer: Chief Business Officer 6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Angela Thedinga director C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kanya Rajangam officer: Chief Medical Officer C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Plc Glaxosmithkline director, 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900